JP2017527286A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527286A5
JP2017527286A5 JP2017512293A JP2017512293A JP2017527286A5 JP 2017527286 A5 JP2017527286 A5 JP 2017527286A5 JP 2017512293 A JP2017512293 A JP 2017512293A JP 2017512293 A JP2017512293 A JP 2017512293A JP 2017527286 A5 JP2017527286 A5 JP 2017527286A5
Authority
JP
Japan
Prior art keywords
mil
composition
oxygen
population
expressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512293A
Other languages
English (en)
Japanese (ja)
Other versions
JP6865160B2 (ja
JP2017527286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/048536 external-priority patent/WO2016037054A1/en
Publication of JP2017527286A publication Critical patent/JP2017527286A/ja
Publication of JP2017527286A5 publication Critical patent/JP2017527286A5/ja
Priority to JP2021063957A priority Critical patent/JP7197213B2/ja
Application granted granted Critical
Publication of JP6865160B2 publication Critical patent/JP6865160B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512293A 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化 Expired - Fee Related JP6865160B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021063957A JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462045782P 2014-09-04 2014-09-04
US62/045,782 2014-09-04
US201562186040P 2015-06-29 2015-06-29
US62/186,040 2015-06-29
PCT/US2015/048536 WO2016037054A1 (en) 2014-09-04 2015-09-04 Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021063957A Division JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Publications (3)

Publication Number Publication Date
JP2017527286A JP2017527286A (ja) 2017-09-21
JP2017527286A5 true JP2017527286A5 (enExample) 2018-10-11
JP6865160B2 JP6865160B2 (ja) 2021-04-28

Family

ID=55440392

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512293A Expired - Fee Related JP6865160B2 (ja) 2014-09-04 2015-09-04 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化
JP2021063957A Active JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021063957A Active JP7197213B2 (ja) 2014-09-04 2021-04-05 正常酸素条件と交互になった低酸素条件における骨髄浸潤リンパ球の活性化

Country Status (13)

Country Link
US (7) US9687510B2 (enExample)
EP (2) EP3188740B1 (enExample)
JP (2) JP6865160B2 (enExample)
KR (1) KR20170067751A (enExample)
CN (1) CN107109364A (enExample)
AU (2) AU2015311761B2 (enExample)
CA (1) CA2959994C (enExample)
DK (1) DK3188740T3 (enExample)
ES (1) ES2877108T3 (enExample)
IL (2) IL250746B (enExample)
MX (1) MX391017B (enExample)
PT (1) PT3188740T (enExample)
WO (1) WO2016037054A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157636A1 (en) 2014-04-10 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
JP2018520679A (ja) 2015-06-29 2018-08-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 免疫チェックポイントキメラ抗原受容体療法
WO2017008019A1 (en) * 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
EP3737743A1 (en) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
JP2021516666A (ja) * 2018-03-22 2021-07-08 ウィンドミル セラピューティクス インコーポレイテッド 前立腺がん特異的髄浸潤リンパ球およびその使用
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
US20210338730A1 (en) * 2018-11-05 2021-11-04 Windmil Therapeutics, Inc. Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereof
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
MX2021006399A (es) * 2018-11-30 2021-07-15 Windmil Therapeutics Inc Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.
CN114072158A (zh) * 2019-03-22 2022-02-18 温德弥尔治疗公司 肺癌特异性骨髓浸润淋巴细胞及其用途
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
WO2025160242A1 (en) * 2024-01-23 2025-07-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of generating tils from cerebro spinal fluid for leptomeningeal disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3243600A (en) 1999-02-23 2000-09-14 Kathleen S. Carswell Improved method of culturing t cells
US6811788B2 (en) * 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
EP2111231A4 (en) * 2007-02-13 2010-12-15 Univ Northeastern METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
EP2364152A4 (en) * 2008-11-03 2013-02-13 Univ Johns Hopkins METHOD FOR PRODUCING AND USING MARKINFILTRATING LYMPHOCYTES (MILS)
BR112014007947A2 (pt) * 2011-10-03 2017-04-18 Univ Los Andes método para monitoramento, diagnóstico e/ou prognóstico de distúrbios relacionados à hipoxia usando nfat5
EP2804625A4 (en) 2012-01-17 2015-10-28 Univ Northeastern METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF
JP2014090678A (ja) * 2012-11-01 2014-05-19 Ito En Ltd 容器詰野菜汁及び／又は果汁含有飲料及びその製造方法、並びに容器詰野菜汁及び／又は果汁含有飲料の呈味劣化防止方法
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
JP2021516666A (ja) * 2018-03-22 2021-07-08 ウィンドミル セラピューティクス インコーポレイテッド 前立腺がん特異的髄浸潤リンパ球およびその使用
MX2021006399A (es) * 2018-11-30 2021-07-15 Windmil Therapeutics Inc Linfocitos infiltrantes de medula osea (mils) que expresan receptores de antigenos quimericos (car), metodo de fabricacion de los mismos y metodo de uso en terapia.

Similar Documents

Publication Publication Date Title
JP2017527286A5 (enExample)
JP2021104048A5 (enExample)
US20230000919A1 (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
Zhou et al. Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 axis
Harden et al. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity
JP2020518289A5 (enExample)
Lundsgaard et al. In vivo control of diabetogenic T-cells by regulatory CD4+ CD25+ T-cells expressing Foxp3
Sungur et al. Utilization of mouse models to decipher natural killer cell biology and potential clinical applications
JP2018518527A5 (enExample)
WO2001038494A1 (en) Method of proliferating natural killer cells
JP2014527820A5 (enExample)
JP2018530534A5 (enExample)
Gao et al. Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease
JP5751277B2 (ja) Ｎｋ細胞活性化方法、これを用いたｎｋ細胞増殖方法及び細胞製造方法並びにｎｋ細胞を含む単核球
JP2023504734A5 (enExample)
JP2019508056A5 (enExample)
Mohammadpour et al. β2-adrenergic signaling regulates graft versus host disease after allogenic transplantation while preserving graft versus leukemia effect
TONG et al. Tissue culture and rapid propagation of rare and endangered Tangtsinia nanchuanica
Hamilton et al. IL-27 enhances inducible foxp3+ treg function to prevent acute graft-versus-host disease lethality
Dhakal et al. " Tailoring" Hematopoietic Progenitor Cell Collection: Impact of a Data-Driven Prediction Algorithm for Blood Volume Processing in Large Volume Leukapheresis
Pan et al. Novel Improvement of Haploidentical Hematopoietic Stem Cell Transplantation for Advanced Refractory/Relapsed Acute Leukemia
Kebriaei et al. Adoptive immunotherapy following umbilical cord blood transplantation using the sleeping beauty system and artificial antigen presenting cells to generate donor-derived T cells expressing a CD19-specific chimeric antigen receptor
HK40064965A (en) Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
Mazur et al. Ex Vivo Expansion of Umbilical Cord Blood T Cells for Adoptive Immunotherapy.
Tabatabaei-Zavareh et al. Stroma-free, serum-free differentiation and expansion of hematopoietic progenitors to the T cell lineage